Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase.
about
Functional SNP of ARHGEF10 confers risk of atherothrombotic strokeIs urotensin-II the new endothelin?The role of urotensin II in cardiovascular and renal physiology and diseasesROCKs as immunomodulators of strokeThe expression of urotensin II receptor (U2R) is up-regulated by interferon-gammaRole of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstrictionMurine and rat cavernosal responses to endothelin-1 and urotensin-II Vasoactive Peptide SymposiumDominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulationThe G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK/ROS Pathway.Mixed-lineage kinase 3 deficiency promotes neointima formation through increased activation of the RhoA pathway in vascular smooth muscle cellsRho kinase: an important mediator of atherosclerosis and vascular disease.Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signallingProtein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosisThe relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cellsUrotensin II alters vascular reactivity in animals subjected to volume overload.Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticityRho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.Association analysis of polymorphisms in ROCK2 with cardiovascular disease in a Chinese population.Role of Rho kinase signalling in healthy and varicose human saphenous veins.Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.Potential Clinical Implications of the Urotensin II Receptor Antagonists.Urotensin II promotes atherosclerosis in cholesterol-fed rabbits.Intra-ventral tegmental area microinjections of urotensin II modulate the effects of cocaine.Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophyUrotensin-II and the cardiovascular system--the importance of developing modulators.Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S PathwayRhoA and resistance artery remodeling.Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges.A closer look at the role of urotensin II in the metabolic syndrome.Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting.The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats.Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?Blockade of Urotensin II Receptor Prevents Vascular Dysfunction.A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndromeA new mechanism of RhoA ubiquitination and degradation: roles of SCF(FBXL19) E3 ligase and Erk2.Urotensin II in cardiovascular regulation.Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2
P2860
Q24293564-1C91C4A7-EFFC-407C-A9AD-96CA1DD96D4AQ24672927-CF8F1813-BE1A-4F5B-B9DA-2044C7B8A6ECQ24675590-2C6C8AB6-C16B-4827-A3E1-35D583C0000AQ26853214-5A7129AD-32D8-49CC-8425-0CBB188C53C1Q28241656-52FAE475-196C-4AA5-876B-51C44104CE7CQ28572971-D85CE506-46D1-4825-8891-3EAF014C951DQ28574132-1E209793-10CB-4474-9BFB-85032BF84C18Q28586459-EBF77EC4-2812-42B1-9E41-10A60760E84BQ33599835-A4F44454-C623-4B91-9EE0-6FF7E3161264Q33655911-42FC7519-7920-40EA-A9DE-DEC03D0C3C98Q33855025-89EE0EDE-8D68-4BF4-8B6C-7FEE1EA98AE5Q33960580-FC6D9FA8-9A86-45F6-B7E6-C06E4F675458Q33991646-2F5158F1-1C82-4B0A-92B5-A813CE63DE6AQ34001118-4F231A62-3261-44FA-A48F-828ED7F32ED6Q34066190-BF285BAE-8EA3-4DFB-AF45-05E33B2EF17BQ34139078-FCB81955-0CB0-4EEC-9B85-B68B83F8E711Q34192302-41922CF9-A788-450C-95CD-AA8982053C4AQ34260110-DC517ED1-D9C4-4BE6-B6EB-E24D8EC30F46Q34362144-D933C80D-3AD6-4461-A218-D0EAAA36FD52Q34551911-5903F7C2-6CB0-4BC0-8F0F-A893A805142CQ35044567-9BC9FAF8-2D6F-40CE-98DE-26DC2614B96DQ35047377-A7AEB68E-DF4C-4537-9C86-F803FCF1FFBBQ35128456-73FA8A8E-9084-422E-AC5B-79806C2DB04BQ35152923-ABE24E61-0204-4E99-8402-0D2D146FBF21Q35243776-75A46F5F-A7EF-4453-94E8-3F12F9B350A4Q35536658-A434637A-33C3-46C3-8D61-A5CD223ACEBBQ35538538-DF5D002F-0C8E-4474-A15D-F66EDFFD5566Q35779239-DDD02C10-6C50-46AF-9507-C206162F6F4CQ35813861-76101C55-FE55-4294-A303-ED1B5FF2F665Q36038081-F6DFB8B3-35B0-41EB-8DBF-E0C55BAA04B2Q36219699-E3D8A2D2-49F9-40C0-8E89-0092C4D5BFAAQ36492706-59A40CA4-E9AE-4667-9F25-F500933EE8B3Q36735227-A28F279A-50C0-4A2A-A620-2567EE4338CBQ36986355-5921E0EE-C1C3-424B-BFC6-AD983DB16412Q37082781-B093FB78-E1CB-41CF-A5D5-20CFC19DF2F9Q37235264-0EA22070-A4DB-4ECB-B3EA-A16AF680938EQ37252109-656C0DD4-FBE5-484D-A309-255B03B3A8CDQ37325302-C335E361-801E-4B6D-AD9A-6B2F7181838FQ37344439-39AEE18F-296E-4195-87AF-BDC0E7A35D5AQ37641575-2560A5C7-FCD0-4415-8248-EC761A198F0E
P2860
Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Human urotensin II-induced con ...... diated by RhoA and Rho-kinase.
@en
Human urotensin II-induced con ...... diated by RhoA and Rho-kinase.
@nl
type
label
Human urotensin II-induced con ...... diated by RhoA and Rho-kinase.
@en
Human urotensin II-induced con ...... diated by RhoA and Rho-kinase.
@nl
prefLabel
Human urotensin II-induced con ...... diated by RhoA and Rho-kinase.
@en
Human urotensin II-induced con ...... diated by RhoA and Rho-kinase.
@nl
P2093
P356
P1433
P1476
Human urotensin II-induced con ...... diated by RhoA and Rho-kinase.
@en
P2093
Bertoglio J
Le Mellionnec E
Scalbert E
P304
P356
10.1161/HH1101.092034
P577
2001-06-01T00:00:00Z